John K. Scott Jr. - 01 Jun 2023 Form 4 Insider Report for NAVIDEA BIOPHARMACEUTICALS, INC.

Role: Director, 10%+ Owner
Signature: /s/ Joseph W. Meyer for John K. Scott, Jr. by power of attorney
Issuer symbol: N/A
Transactions as of: 01 Jun 2023
Net transactions value: $0
Form type: 4
Filing time: 15 Jun 2023, 18:35:06 UTC
Previous filing: 30 Nov 2022
Next filing: 30 Jun 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NAVB	Series G Redeemable Preferred Stock	Other		-990	-30%		2,270	01 Jun 2023	Direct	F1
transaction	NAVB	Common Stock	Award		+11,508,672	+143%		19,555,832	05 Jun 2023	Direct	F2
holding	NAVB	Common Stock						10,139	01 Jun 2023	By spouse and children	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NAVB	Series J Convertible Preferred Stock	Purchase	$1,196,900	+11,969		$100.00^*	11,969	01 Jun 2023	Common Stock	11,508,672	$0.1040	Direct	F1, F4
transaction	NAVB	Series J Convertible Preferred Stock	Conversion of derivative security	$1,196,900	-11,969	-100%	$100.00^*	0	05 Jun 2023	Common Stock	11,508,672	$0.1040	Direct	F4, F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Navidea entered into a Stock Exchange Agreement with the Reporting Person, pursuant to which he surrendered 990 shares of Series G Redeemable Preferred Stock, par value $.001 per share, and $68,853.22 of accrued and unpaid dividends thereon in exchange for 11,969 shares of Series J Convertible Preferred Stock, par value $.001 per share.
F2	Series J Convertible Preferred Stock, par value $.001 per share was converted into Common Stock.
F3	Includes 2,639 shares of Common Stock owned by the Reporting Person's spouse and 7,500 shares of Common Stock owned by the Reporting Person's children. The Reporting Person may be deemed tohave shared voting and/or dispositive power with respect to such shares.
F4	Series J Convertible Preferred Stock, par value $.001 per share, is convertible at any time and has no expiration date.
F5	The Reporting Person converted 11,969 shares of Series J Convertible Preferred Stock, par value $.001 per share, into 11,508,672 shares of Common Stock.